U.S. Court of Appeals for the Third Circuit
Lipitor Antitrust Litigation v.
September 8, 2026
Summary
The Third Circuit affirmed the district court’s grant of summary judgment to Ranbaxy and its denial of class certification, holding that the plaintiffs lacked antitrust standing because they failed to show that, but for the settlement, the FDA would have approved the generic Lipitor earlier. Accordingly, the plaintiffs could not serve as adequate class representatives. The court also affirmed that the class certification motions were properly denied because the named plaintiffs no longer had a live claim.